Deakin University
Browse

File(s) under permanent embargo

Protein kinase C isozymes as potential therapeutic targets in immune disorders

journal contribution
posted on 2008-05-01, 00:00 authored by M Lee, Wei DuanWei Duan, S L Tan
Background: Members of the protein kinase C (PKC) family are key signalling mediators in immune responses, and pharmacological inhibition of PKCs may be useful for treating immune-mediated diseases. Objective: To review and discuss the insights gained so far into various PKC isozymes and the therapeutic potential and challenges of developing PKC inhibitors for immune disorder therapy. Methods: A literature review of the role of PKCs in immune cell signalling and recent studies describing immune functions associated with PKC isozyme deficiency in relevant mouse disease models, followed by specific case studies of current and potential therapeutic strategies targeting PKCs. Results/conclusion: There is vast amount of data supporting PKC isozymes as attractive drug targets for certain immune disorders. Although the development of specific PKC isozyme inhibitors has been challenging, some progress has been made. It remains to be seen if broad-scale or isozyme-selective inhibition of PKC will have clinical efficacy.

History

Journal

Expert opinion on therapeutic targets

Volume

12

Issue

5

Pagination

535 - 552

Publisher

Informa Healthcare

Location

London, England

ISSN

1472-8222

eISSN

1744-7631

Language

eng

Publication classification

C1 Refereed article in a scholarly journal

Copyright notice

2008, Informa UK Ltd